|
|
Volumn 10, Issue 2, 2011, Pages 116-117
|
|
The risky business of drug development in neurology
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
SEMAGACESTAT;
ALZHEIMER DISEASE;
CLINICAL TRIAL;
COGNITIVE DEFECT;
DRUG MANUFACTURE;
DRUG RESEARCH;
DRUG SAFETY;
HEALTH CARE COST;
HUMAN;
MIGRAINE;
NEUROLOGIC DISEASE;
NOTE;
PAIN;
PARKINSON DISEASE;
PATIENT SAFETY;
PRIORITY JOURNAL;
RISK ASSESSMENT;
ANIMALS;
COMMERCE;
DRUG DISCOVERY;
DRUG INDUSTRY;
HUMANS;
NEUROLOGY;
RISK;
|
|
EID: 78751539901
PISSN: 14744422
EISSN: None
Source Type: Journal
DOI: 10.1016/S1474-4422(11)70004-7 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|
